Abstract |
We examined the effects of U50,488, a kappa-opioid receptor agonist, and flurbiprofen axetil, a nonsteroidal antiinflammatory drug, in a visceral pain model using conscious rats. U50,488 produced visceral antinociception, but exaggerated the adverse effects on the central nervous system (CNS) at 0.9 mg/kg or more. Naloxone completely antagonized these effects. Flurbiprofen axetil produced visceral antinociception, but exaggerated the adverse effects on the CNS at 80 mg/kg. Coadministration of U50,488 (0.27 mg/kg) and flurbiprofen axetil (50 mg/kg) produced intense visceral antinociception without adverse effects on the CNS, implying therapeutic efficacies of coadministration of kappa-opioid receptor-agonists and nonsteroidal antiinflammatory drugs on visceral pain.
|
Authors | Takayuki Kitamura, Makoto Ogawa, Yoshitsugu Yamada |
Journal | Anesthesia and analgesia
(Anesth Analg)
Vol. 108
Issue 6
Pg. 1964-6
(Jun 2009)
ISSN: 1526-7598 [Electronic] United States |
PMID | 19448232
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents, Non-Steroidal
- Narcotic Antagonists
- Receptors, Opioid, kappa
- Flurbiprofen
- Naltrexone
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
- flurbiprofen axetil
|
Topics |
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
(therapeutic use)
- Abdominal Muscles
(drug effects)
- Analgesics, Non-Narcotic
(therapeutic use)
- Animals
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Catheterization
- Dose-Response Relationship, Drug
- Drug Synergism
- Flurbiprofen
(analogs & derivatives, therapeutic use)
- Male
- Muscle Contraction
(drug effects)
- Naltrexone
(pharmacology)
- Narcotic Antagonists
(pharmacology)
- Pain
(drug therapy)
- Pain Measurement
(drug effects)
- Physical Stimulation
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid, kappa
(agonists)
- Rectum
(physiology)
|